跳转至内容
Merck
  • [The pharmacokinetics of propranolol and its conjugated metabolites in patients with chronic ischemic heart disease and arterial hypertension with a one-time and course intake of the drug].

[The pharmacokinetics of propranolol and its conjugated metabolites in patients with chronic ischemic heart disease and arterial hypertension with a one-time and course intake of the drug].

Eksperimental'naia i klinicheskaia farmakologiia (1995-11-01)
V G Belolipetskaia, D S Rumiantsev, V K Piotrovskiĭ, V I Metelitsa, S G Duda, T P Ostrovskaia, E V Kokurina, S Iu Martseva, E V Bochkareva, N P Filatova
摘要

Pharmacokinetics of propranolol (P), 4-hydroxy-propranolol sulfate (4HOP-Sulf), and glucoronides of pharmacologically active S-enantiomer P (S-PG) and ballast R-enantiomer of P (R-PG) in the blood serum of 21 patients with chronic ischemic heart disease and/or arterial hypertension has been studied at a single and course oral P administration. The values od AUC and T1/2 for potentially active 4HOP-Sulf were significantly higher than those for unchanged P at a single and course administration. The values od AUC and T1/2 for for S-PG were approximately three times higher than those for P-PG after both a single and course administration. Thus the results presented show that potentially active 4HOP-Sulf and S-PG (which undergoes a partial deconjugation in an organism at oral administration) may contribute essentially to the value and duration of the P pharmacological effect.

材料
货号
品牌
产品描述

Supelco
(±)-4-Hydroxypropranolol hydrochloride, analytical standard